Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer

被引:37
|
作者
Shen, Mengqin [1 ,3 ]
Zhao, Xiaoping [1 ,3 ]
Zhao, Li [1 ,3 ]
Shi, Liang [1 ,3 ]
An, Shuxian [1 ,3 ]
Huang, Gang [1 ,2 ,3 ]
Liu, Jianjun [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai 200127, Peoples R China
[2] Shanghai Univ Med & Hlth Sci, Collaborat Sci Res Ctr, Shanghai Key Lab Mol Imaging, Shanghai 200093, Peoples R China
[3] Shanghai Jiao Tong Univ, Inst Nucl Med, Sch Med, Shanghai 200127, Peoples R China
基金
中国国家自然科学基金;
关键词
TIGAR; Met; Non-small-cell lung cancer; Metastasis; Epithelial-mesenchymal transition; TP53-INDUCED GLYCOLYSIS; APOPTOSIS REGULATOR; C-MET; OXIDATIVE STRESS; METABOLISM; IDENTIFICATION; PROGRESSION; ACTIVATION; PATHWAYS; RECEPTOR;
D O I
10.1186/s12943-018-0839-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
TIGAR is a p53 target gene that is known to protect cells from ROS-induced apoptosis by promoting the pentose phosphate pathway. The role of TIGAR in tumor cell invasion and metastasis remains elusive. Here we found that downregulation of TIGAR reduced the invasion and metastasis of NSCLC cells in vitro and in vivo. Immunohistochemical analysis of 72 NSCLC patients showed that TIGAR and Met protein expression was positively correlated with late stages of lung cancer. Besides, patients with high co-expression of TIGAR and Met presented a significantly worse survival. In addition, we found that Met signaling pathway is involved in TIGAR-induced invasion and metastasis. Our study indicates that TIGAR/Met pathway may be a novel target for NSCLC therapy. It is necessary to evaluate the expression of TIGAR before Met inhibitors are used for NSCLC treatment.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target
    Spitaleri, Gianluca
    Aliaga, Pamela Trillo
    Attili, Ilaria
    Del Signore, Ester
    Corvaja, Carla
    Corti, Chiara
    Uliano, Jacopo
    Passaro, Antonio
    de Marinis, Filippo
    CANCERS, 2023, 15 (19)
  • [32] Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
    Tan, Yi-Hung Carol
    Mirzapoiazova, Tamara
    Won, Brian M.
    Zhu, Li
    Srivastava, Minu K.
    Vokes, Everett E.
    Husain, Aliya N.
    Batra, Surinder K.
    Sharma, Sherven
    Salgia, Ravi
    SCIENTIFIC REPORTS, 2017, 7
  • [33] Quantification of serum MET in non-small-cell lung cancer and its clinical significance
    Li, Detao
    Li, Fengzeng
    Wu, Yanfeng
    Zhou, Dandan
    Chen, Hui
    CLINICAL BIOCHEMISTRY, 2015, 48 (03) : 110 - 114
  • [34] Spine Metastasis Is Associated with the Development of Brain Metastasis in Non-Small-Cell Lung Cancer Patients
    Cha, Hyung-Keun
    Ryu, Woo-Kyung
    Lee, Ha-Young
    Kim, Hyun-Jung
    Ryu, Jeong-Seon
    Lim, Jun-Hyeok
    MEDICINA-LITHUANIA, 2024, 60 (01):
  • [35] Crizotinib in the treatment of non-small-cell lung cancer
    Forde, Patrick M.
    Rudin, Charles M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1195 - 1201
  • [36] Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis
    Zhu, Tianhao
    Bao, Xunxia
    Chen, Mingyu
    Lin, Rui
    Zhuyan, Jianan
    Zhen, Timing
    Xing, Kaichen
    Zhou, Wei
    Zhu, Sibo
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [37] A Systematic Review of Mesenchymal Epithelial Transition Factor (MET) and Its Impact in the Development and Treatment of Non-Small-Cell Lung Cancer
    Boden, Embla
    Svereus, Fanny
    Olm, Franziska
    Lindstedt, Sandra
    CANCERS, 2023, 15 (15)
  • [38] YAP signaling is involved in WDR1-regulated proliferation and migration of non-small-cell lung cancer cells
    An, Ran
    Wang, Junyan
    Chen, Xuan
    Xu, Ruifeng
    Hu, Jisheng
    Liu, Zhongying
    Wei, Chanjuan
    Zhang, Chenxi
    Yuan, Baiyin
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2022, 247 (18) : 1619 - 1629
  • [39] Amrubicin for non-small-cell lung cancer and small-cell lung cancer
    Kurata, Takayasu
    Okamoto, Isamu
    Tamura, Kenji
    Fukuoka, Masahiro
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 499 - 504
  • [40] Amrubicin for non-small-cell lung cancer and small-cell lung cancer
    Takayasu Kurata
    Isamu Okamoto
    Kenji Tamura
    Masahiro Fukuoka
    Investigational New Drugs, 2007, 25 : 499 - 504